Results 41 to 50 of about 178,517 (322)

Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA). [PDF]

, 1994
The gene responsible for X-linked agammaglobulinemia (XLA) has been recently identified to code for a cytoplasmic tyrosine kinase (Bruton's agammaglobulinemia tyrosine kinase, BTK), required for normal B cell development. BTK, like many other cytoplasmic
Chen, SH, Hagemann, T, Kwan, SP, Nilsson, L, Ochs, HD, Rawlings, DJ, Saffran, DC, Smith, CI, Vihinen, M, Witte, ON, Zhang, M, Zhu, Q   +11 more
core   +1 more source

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant, AJ Mohamed, BD Smith, BJ Druker, C Chung, C Dos Santos, C Thiede, C Venkataraman, CC Smith, CK Hahn, F Heidel, F Honda, G Juliusson, H Kiyoi, HS Ma, J Adolfsson, JA Dubovsky, JA Dubovsky, JA Woyach, JA Woyach, JB Petro, K Fiedler, KU Birkenkamp, L Zaitseva, M Levis, M Nakao, ML Wang, N Feldhahn, NJ Horwood, PP Zarrinkar, Q Xu, RF Schlenk, RM Stone, S Knapper, S Meshinchi, SA Ezell, SA Rushworth, SA Rushworth, SA Rushworth, SA Rushworth, T Kindler, T Matsunaga, T Oellerich, T-l Gu, V Vijayan, W Gao, Y Alvarado, Y Baba, Y Yamamoto, Y-T Tai   +49 more
core   +2 more sources

Switching immune signals on and off

eLife, 2015
Bruton's tyrosine kinase, an enzyme that is important for B cell function, can be activated in a number of ways.
Nam Chu, Philip A Cole
doaj   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors

Burns & Trauma, 2014
Tec family kinases, which include tyrosine kinase expressed in hepatocellular carcinoma (TEC), Bruton's tyrosine kinase (BTK), interleukin (IL)-2-inducible T-cell kinase (ITK), tyrosine-protein kinase (TXK), and bone marrow tyrosine kinase on chromosome ...
Le Qiu, Fei Wang, Sheng Liu, Xu-Lin Chen
doaj   +1 more source

Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism [PDF]

, 2015
© 2015 Wiley Periodicals, Inc. Acknowledgement Grant sponsor: State of Lower Saxony-Israel Research Cooperation; Grant number: ZN2035; Grant sponsor:German Research Council; Grant number: SFB/TRR43 and FOR1336; Grant sponsor: Parkinson UK; Grant number ...
Akarasereenont, Amedei, Angstwurm, Balachandra, Bermejo, Bettelli, Boucheron, Brenner, Brück, Byrd, Chatterjee, Chiang, Coles, Cossburn, Cuzzocrea, Cuzzocrea, Das Sarma, Doyle, Dugo, Fischer, Fitzner, George, Ghoreschi, Goldmann, Gorina, Gray, Haider, Hanamsagar, Hanisch, Hanisch, Hanisch, Hoffmann, Hong, Horwood, Jaleel, Jefferies, Kahlenberg, Kann, Kawai, Kelly, Khan, Krady, Langer-Gould, Lee, Lehmann, Lehmann-Horn, Lehnardt, Levitzki, Li, Lin, Liu, Liu, Lopez-Talavera, Mangla, Marzocco, Mattsson, Mauro, McDonald, McGeer, Mehta, Mijovic, Mohamed, Moore, Muelas-Serrano, Mukhopadhyay, Murray, Novogrodsky, Perry, Prinz, Raghavan, Ramdas, Regen, Rossum, Ruetten, Sagara, Scheffel, Schmidt, Schweingruber, Simmons, Soltoff, Spitzer, Stewart, Terada, Turpaev, Tönges, Wang, Wang, Weber, Weber, Wüst, Xiao, Zhang, Zorn   +92 more
core   +1 more source

Bruton tyrosine kinase inhibitors for multiple sclerosis

Nature Reviews Neurology, 2023
Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated worsening of disability, which is assumed to be mainly associated with transient infiltration of peripheral immune cells into the central nervous system (CNS). However, approved therapies are less effective at slowing disability accumulation in patients with MS ...
Julia Krämer, Amit Bar-Or, Timothy J. Turner, Heinz Wiendl   +3 more
openaire   +2 more sources

Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials [PDF]

Journal of Immunotherapy and Precision Oncology, 2022
Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects.
Thura Win Htut, Myat Min Han, Kyaw Zin Thein   +2 more
doaj   +1 more source

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs

Haematologica, 2019
Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated for example by the Bruton's tyrosine kinase (BTK) inhibitor,
Debora Soncini, Stefania Orecchioni, Samantha Ruberti, Paola Minetto, Claudia Martinuzzi, Luca Agnelli, Katia Todoerti, Antonia Cagnetta, Maurizio Miglino, Marino Clavio, Paola Contini, Riccardo Varaldo, Micaela Bergamaschi, Fabio Guolo, Mario Passalacqua, Alessio Nencioni, Fiammetta Monacelli, Marco Gobbi, Antonino Neri, Giovanni Abbadessa, Sudharshan Eathiraj, Brian Schwartz, Francesco Bertolini, Roberto M. Lemoli, Michele Cea   +24 more
doaj   +1 more source

Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis. [PDF]

Postep Psychiatr Neurol, 2023
In this review, we have highlighted a new class of drugs, Bruton's tyrosine kinase (BTK) inhibitors, and summarized the results of recent clinical trials in the treatment of multiple sclerosis.Multiple sclerosis (MS) is considered an autoimmune disease of the central nervous system, in which B-lymphocytes and myeloid cells, such as macrophages and ...
Shulga O, Chabanova A, Kotsiuba O.
europepmc   +3 more sources